Novartis’s $900 Million BoomRay Licence Names No Target, No Isotope and No Upfront
- BoomRay Pharmaceuticals of Suzhou said on 22 September 2026 that it has granted Novartis an exclusive global licence to an undisclosed preclinical radioligand therapy. BoomRay is eligible for up to $900m, covering an upfront payment and development, regulatory and sales milestones, plus royalties on global net sales.
- The release does not name the asset’s target, isotope or indication, and does not separate the upfront from the milestones. BFC Group advised BoomRay.
- Shiva Malek, Novartis’s global head of oncology in biomedical research, said the deal complements its growing radioligand portfolio and its strategy of pairing external innovation with internal research. BoomRay describes itself as clinical-stage; the PatSnap Synapse database records a Series A of nearly RMB300m in 2022.
- Novartis built the franchise by acquisition: Advanced Accelerator Applications for $3.9bn and Endocyte for $2.1bn in 2018, bringing Lutathera and what became Pluvicto, then Mariana Oncology in 2024 for $1bn upfront plus up to $750m in milestones. The licence landed a day after Telix agreed to buy ITM for $1.65bn upfront.
Deal read
The total has no denominator. Without an upfront, a target or an isotope, $900 million is a ceiling, not a valuation.
- Nothing in the release can be valued from outside. The asset is preclinical, its target and isotope are withheld, and the upfront is folded into the headline. Novartis’s own Mariana deal separated $1bn upfront from $750m in milestones. The same buyer disclosed a split two years ago; this release does not.
- The market leader is buying earlier. Novartis already holds the two approved radioligand anchors from its 2018 acquisitions, and paid for a preclinical pipeline with Mariana. Licensing a single undisclosed preclinical asset from a Suzhou biotech extends the same search further upstream, where the price of an option is set by milestones rather than cash.
- Molecules and isotopes are now being bought separately. In two days, one company paid $1.65bn in stock for the isotope supply radioligand developers depend on, and the incumbent licensed another molecule to put an isotope on. Those are the two scarce inputs in the field, and they are being priced by different buyers.